IO-108,pembrolizumab,cemiplimab 
Immune-Onc Therapeutics,Merck,Regeneron
['io-108']
$imnp immune-onc therapeutics to present phase 1 results for io-108 at aacr 2023. more info: $xbi $ibb $xph $pph
Latest BioPharma/Biotech News. Daily $XBI $XPH Market Movers

Database: https://t.co/IBOqbSoYuc
Clinical trial tools: https://t.co/A77u9Q84Dc  https://t.co/lvTtwarrGT